Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
默克默克(US:MRK) Barrons·2026-02-26 01:38

公司研发进展 - 默克公司的双药HIV治疗方案在三期临床试验中疗效与吉利德的明星药物Biktarvy相当 [1] - 该双药HIV方案目前正处于美国食品药品监督管理局的审评阶段 [1] 公司战略背景 - 默克公司正在为其关键药物Keytruda的专利悬崖做准备 [1]

Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. - Reportify